Post Marketing Surveillance/Drug Sampling
The WSMA strongly endorses physicians' participation in post-marketing
surveillance, including working with the State Department of Health to
seek grant or contract funds to assure the surveillance program increases.
The WSMA opposes any "novel" legislation or regulatory action that would
restrict the reasonable conduct of drug sampling of licensed
practitioners. (Res 37, C 87; Res 5, A-90) (Reaffirmed A-23)
Return to the WSMA Policy Compendium index
Abbreviations for House of Delegates report origination:
EC – Executive Committee; BT – Board of Trustees; CPA – Council on
Professional Affairs; JC – Judicial Council; CHS – Community and Health
Services